|
04 Jun 2019 |
Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
|
|
04 Jun 2019 |
Cellenkos, Inc. Initiates Phase 1 Clinical Trial of CK0801 for Treatment of Bone Marrow Failure Syndromes
|
|
04 Jun 2019 |
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients
|
|
04 Jun 2019 |
NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
|
|
04 Jun 2019 |
Strand Therapeutics Announces $6 Million Seed Financing to Advance its Programmable mRNA Therapeutics Platform
|
|
03 Jun 2019 |
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
|
|
02 Jun 2019 |
Talaris Therapeutics Presents Data Demonstrating Improved Quality of Life for Patients Treated with FCR001
|
|
02 Jun 2019 |
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
|
|
01 Jun 2019 |
Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
|
|
01 Jun 2019 |
Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
|
|
31 May 2019 |
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
|
|
31 May 2019 |
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
|
|
30 May 2019 |
Mesoblast initiates rolling submission of biologics license application (BLA) to U.S. FDA for remestemcel-l in the treatment of acute graft versus host disease
|
|
29 May 2019 |
Freeline presents preclinical data and phase 1/2 study design of the FLT190 AAV gene therapy for Fabry Disease
|
|
29 May 2019 |
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
|
|
28 May 2019 |
The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress
|
|
24 May 2019 |
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
|
|
23 May 2019 |
Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
|
|
23 May 2019 |
Iovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patients Who Have Progressed on or After Chemotherapy
|
|
23 May 2019 |
EpiBone, Inc. Receives FDA Clearance to Commence its First-In-Human, Phase 1/2 Trial of its Bone Product, EB-CMF
|
|
22 May 2019 |
EXUMA Biotechnology’s Affiliate Shanghai PerHum Therapeutics Announces Preliminary Results of Two First-in-Human Solid Tumor CAR-T Products
|
|
22 May 2019 |
Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
|
|
18 May 2019 |
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
|
|
16 May 2019 |
Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD
|
|
16 May 2019 |
Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus
|
